Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned fundraising through debt or equity. No specific comments or disclosures were made regarding raising capital via debt or equity. The company mentioned capital expenditure plans with a capex budget of INR 75-80 crore for opening new centers and digital initiatives, plus INR 8-8.5 crore for PET-CT equipment, indicating internal funding or existing resources. The management stated capital has not been a constraint for expansion, implying reliance on internal accruals or other sources. No explicit intention or schedule for fundraising activitie

Any current/future capex/capital investment/strategic investment?

Capex for FY24 is expected to be INR 75 crore to INR 80 crore to open 15 new centres annually, including INR 2-3 crore for digital initiatives like revamping radiology PACS and centralizing CRM software. Additional capex of INR 8 crore to INR 8.5 crore planned for PET-CT equipment in Vizag cluster. Majority of capex will be outside Hyderabad, focusing on newer geographies like Kolkata, Rajahmundry, and expansion in Andhra Pradesh and West Bengal. Strategic plan involves opening 4 to 5 large hubs per year and multiple spokes around these hubs for dense clustering and profitability. Continuous e

Future growth expectations in sales/revenue/volumes?

The company expects double-digit year-on-year growth in volumes, with Q4-to-Q4 and Q3-to-Q3 already showing strong growth. Guidance for overall revenue growth is about 14-15% annually, driven by both existing and new centres. Existing centres contribute roughly 9-10% growth, while newer centres add around 4-5%. The expansion plan includes opening around 15 new centres per year, with a mix of hubs and spokes. New centres are in early stages, expected to mature and contribute significantly in 2-3 years (e.g., Tirupati centre expected to generate INR 17-20 crore annual revenue at maturity). Volum

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects a revenue growth rate of about 14%-15% CAGR going forward, driven mainly by volume growth and addition of new centres. Existing centres are anticipated to contribute approximately 9%-10% CAGR growth, while newer centres add another 4%-5%. EBITDA margins are expected to sustain around 40%, even with the opening of new hubs and spokes. For the near term, growth from the current network is projected at about 10%-11%, with newer centres supporting overall growth of 14%-15%. Price increases on select tests may contribute an incremental ~0.8%-1% to revenues. At maturity, individu

Vijaya Diagnostic Centre LtdQ4 FY23Healthcare Services

Vijaya Diagnostic Centre Ltd Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,445.7P/E: 79.4Market Cap: ₹14.9K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company expects double-digit year-on-year growth in volumes, with Q4-to-Q4 and Q3-to-Q3 already showing strong growth.
Guidance for overall revenue growth is about 14-15% annually, driven by both existing and new centres.
Existing centres contribute roughly 9-10% growth, while newer centres add around 4-5%.
The expansion plan includes opening around 15 new centres per year, with a mix of hubs and spokes.
New centres are in early stages, expected to mature and contribute significantly in 2-3 years (e.g., Tirupati centre expected to generate INR 17-20 crore annual revenue at maturity).
Volume growth forms about 13-13.5% of the expected 15% revenue growth, with minimal contribution from price increases.
The company is confident in sustaining 40% EBITDA margin alongside this growth.

Margin guidance

Category 3

The company expects a revenue growth rate of about 14%-15% CAGR going forward, driven mainly by volume growth and addition of new centres.
Existing centres are anticipated to contribute approximately 9%-10% CAGR growth, while newer centres add another 4%-5%.
EBITDA margins are expected to sustain around 40%, even with the opening of new hubs and spokes.
For the near term, growth from the current network is projected at about 10%-11%, with newer centres supporting overall growth of 14%-15%.
Price increases on select tests may contribute an incremental ~0.8%-1% to revenues.
At maturity, individual new centres like Tirupati are expected to generate annual revenues between INR 17-20 crore.
The company is confident in delivering consistent performance and healthy profitability margins in future years.

See what Vijaya Diagnostic Centre Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript does not mention any current or planned fundraising through debt or equity.
No specific comments or disclosures were made regarding raising capital via debt or equity.
The company mentioned capital expenditure plans with a capex budget of INR 75-80 crore for opening new centers and digital initiatives, plus INR 8-8.5 crore for PET-CT equipment, indicating internal funding or existing resources.
The management stated capital has not been a constraint for expansion, implying reliance on internal accruals or other sources.
No explicit intention or schedule for fundraising activities was disclosed in the Q4 FY23 earnings call.

Order book

The transcript and document do not explicitly mention any details regarding the current or expected order book or pending orders for VDCL. Key points gathered related to business activities include: - VDCL is actively looking at inorganic growth opportunities with some ongoing discussions but no concrete deals yet (Page 19). - The company expects to open 15 new centers in FY24, including hubs and spokes, with expansion plans especially in Kolkata and adjacent geographies (Pages 7, 15, 19). - They maintain guidance of 14-15% growth based on existing and new centers (Page 10). - No specific mention of order book value or pending orders is made in the earnings call transcript. Hence, there is no direct information on order book or pending orders available in the provided transcript.

See what Vijaya Diagnostic Centre Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Capex for FY24 is expected to be INR 75 crore to INR 80 crore to open 15 new centres annually, including INR 2-3 crore for digital initiatives like revamping radiology PACS and centralizing CRM software.
Additional capex of INR 8 crore to INR 8.5 crore planned for PET-CT equipment in Vizag cluster.
Majority of capex will be outside Hyderabad, focusing on newer geographies like Kolkata, Rajahmundry, and expansion in Andhra Pradesh and West Bengal.
Strategic plan involves opening 4 to 5 large hubs per year and multiple spokes around these hubs for dense clustering and profitability.
Continuous equipment upgrades, opting for technology upgrades without full replacements to keep state-of-the-art facilities.
Expansion includes new facilities like 3 Tesla MRI and cardiac CT in Kolkata, addressing underserved diagnostic services.

Track Vijaya Diagnostic Centre Ltd — get its next earnings analysis in your feed

How does Vijaya Diagnostic Centre Ltd rank vs peers in Healthcare Services?

Pro feature

ThisVijaya Diagnostic Centre Ltd

Rev 3Mar 3

See where Vijaya Diagnostic Centre Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Vijaya Diagnostic Centre Ltd rank in Healthcare Services?

Compare Vijaya Diagnostic Centre Ltd against every Healthcare Services company (Q4 FY23) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Vijaya Diagnostic Centre Ltd's management said in earlier quarters

Others in Healthcare Services this season

Narayana Hrudayalaya Ltd (Q2 FY27)
Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27
Artemis Medicare Services Ltd (Q2 FY27)
Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service
Max Healthcare Institute Ltd (Q2 FY27)
Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio
Indegene Ltd (Q2 FY27)
Revenue from operations for Q2 FY27: INR 11,223 million, up 39.5% YoY (Page 23, 15, 4) . Key investor presentation takeaways from Indegene Ltd's Q2 FY27 investo

Compare:vs Apollo Hospitals Enterprise Ltd vs Manipal Health Enterprises Ltd vs Max Healthcare Institute Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Vijaya Diagnostic Centre Ltd Q4 FY23 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Vijaya Diagnostic Centre Ltd rank in Healthcare Services?

Continue your research

What Vijaya Diagnostic Centre Ltd's management said in earlier quarters

Others in Healthcare Services this season